About this time last year, DNA sequencing giant Illumina upped its financial projections, estimating its sales would grow 20 percent year-over-year. It exceeded that goal, with revenue rising 21 percent to $3.33 billion by the end of 2018.
It’s a different financial story this summer. On Monday, Illumina (NASDAQ: ILMN) informed the markets that it had overshot the mark with its 2019 estimates. The news reflects a slowdown in the demand for mail-in genetic testing kits and a lag in the rollout of some of the government-led population studies for which Illumina provides DNA sequencing tools. The company, which previously… Read more »
UNDERWRITERS AND PARTNERS